Q3 EPS Estimate for Janux Therapeutics Raised by Analyst

Janux Therapeutics, Inc. (NASDAQ:JANX) – Research analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Janux Therapeutics in a note issued to investors on Monday, August 10th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.45) per share for the quarter, up from their previous forecast of ($0.50). The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.71) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($1.69) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at ($0.56) EPS, Q3 2027 earnings at ($0.58) EPS, Q4 2027 earnings at ($0.69) EPS, FY2027 earnings at ($2.36) EPS, FY2028 earnings at ($2.72) EPS and FY2029 earnings at ($1.11) EPS.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.10). The firm had revenue of $10.27 million during the quarter, compared to analyst estimates of $19.07 million.

Several other equities analysts have also weighed in on JANX. UBS Group lowered shares of Janux Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $57.00 to $15.00 in a report on Wednesday, April 15th. Guggenheim cut their price target on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Monday, July 20th. Wedbush decreased their price objective on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, May 8th. Finally, Truist Financial reiterated a “buy” rating and issued a $26.00 price objective (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $37.58.

Janux Therapeutics Trading Up 0.7%

Shares of JANX opened at $16.52 on Wednesday. Janux Therapeutics has a 12-month low of $12.12 and a 12-month high of $35.34. The firm has a market capitalization of $1.01 billion, a P/E ratio of -10.07 and a beta of 2.50. The firm has a 50-day moving average price of $15.14 and a 200 day moving average price of $14.50.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Janux Therapeutics during the 4th quarter worth approximately $34,000. Versant Capital Management Inc raised its position in Janux Therapeutics by 42.8% in the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock valued at $40,000 after purchasing an additional 784 shares during the period. Osaic Holdings Inc. raised its position in Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after purchasing an additional 3,037 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Janux Therapeutics during the fourth quarter worth $51,000. Finally, Tower Research Capital LLC TRC lifted its stake in Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after purchasing an additional 2,502 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the transaction, the insider owned 75,941 shares of the company’s stock, valued at $1,065,452.23. This trade represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is owned by insiders.

Key Janux Therapeutics News

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $1.69 from $1.89, closer to the consensus loss estimate of $1.71. The firm also narrowed projected losses for Q3 2026 to $0.45 from $0.50 and Q4 2026 to $0.51 from $0.52.
• Positive Sentiment: Forecasts for 2027 also improved in the first three quarters: Q1 EPS was revised to a loss of $0.53 from $0.56, Q2 to a loss of $0.56 from $0.59, and Q3 to a loss of $0.58 from $0.63. The FY2027 loss estimate improved to $2.36 from $2.44.
• Neutral Sentiment: The reported short-interest data showed zero shares sold short and a zero-day days-to-cover ratio, making it unreliable for assessing short-covering or bearish positioning.
• Negative Sentiment: HC Wainwright lowered its Q4 2027 EPS forecast to a loss of $0.69 from $0.66, FY2028 to a loss of $2.72 from $2.51, FY2029 to a loss of $1.11 from $1.00, and FY2030 profit to $0.97 from $1.06. These cuts suggest a weaker long-term earnings trajectory despite better near-term expectations.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.